Search research articles
Contact Us
Filters
Showing results (201-210 of 219) with videos related to
Page
of 22
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2018
Safety and dose modification for patients receiving niraparib
J S Berek, U A Matulonis, U Peen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 27, 2022
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer
K E Francis, S I Kim, M Friedlander, et al.
ESMO Open
|
February 26, 2026
Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial
L Paracchini, A Velle, P Di Gennaro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 3, 2019
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
U A Matulonis, R Shapira-Frommer, A D Santin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2021
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
K N Moore, A M Oza, N Colombo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 13, 2025
Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial
H Blons, J Abdelli, S Landman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 30, 2022
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial
J S Frenel, J W Kim, N Aryal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2023
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
E Pujade-Lauraine, F Selle, G Scambia, et al.
Gynecologic Oncology
|
September 15, 2019
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer
I Vergote, A du Bois, A Floquet, et al.
British Journal of Cancer
|
December 4, 1998
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group
K Aabo, M Adams, P Adnitt, et al.
Page
of 22
Search research articles
Search
Showing results (201-210 of 219) with videos related to
Sort By:
Page
of 22
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2018
Safety and dose modification for patients receiving niraparib
J S Berek, U A Matulonis, U Peen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 27, 2022
The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer
K E Francis, S I Kim, M Friedlander, et al.
ESMO Open
|
February 26, 2026
Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial
L Paracchini, A Velle, P Di Gennaro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 3, 2019
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
U A Matulonis, R Shapira-Frommer, A D Santin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2021
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
K N Moore, A M Oza, N Colombo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 13, 2025
Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial
H Blons, J Abdelli, S Landman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 30, 2022
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial
J S Frenel, J W Kim, N Aryal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 5, 2023
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
E Pujade-Lauraine, F Selle, G Scambia, et al.
Gynecologic Oncology
|
September 15, 2019
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer
I Vergote, A du Bois, A Floquet, et al.
British Journal of Cancer
|
December 4, 1998
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group
K Aabo, M Adams, P Adnitt, et al.
Page
of 22